SEARCH:   Advanced

Blood, 1 September 2004, Vol. 104, No. 5, pp. 1442-1449. Prepublished online as a Blood First Edition Paper on May 20, 2004; DOI 10.1182/blood-2004-02-0588. This Article Full Text (PDF) All Versions of this Article: 2004-02-0588v1 104/5/1442    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Harata, M. Articles by Asano, S. Search for Related Content PubMed PubMed Citation Articles by Harata, M. Articles by Asano, S. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 19, 2004 Accepted April 13, 2004 CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells Masamitsu Harata, Yasushi Soda, Kenzaburo Tani*, Jun Ooi, Tomoko Takizawa, Minghan Chen, Yuansong Bai, Kiyoko Izawa, Seiichiro Kobayashi, Akira Tomonari, Fumitaka Nagamura, Satoshi Takahashi, Kaoru Uchimaru, Tohru Iseki, Takashi Tsuji, Tsuneo A Takahashi, Kanji Sugita, Shinpei Nakazawa, Arinobu Tojo, Kazuo Maruyama, and Shigetaka Asano Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science ,The University of Tokyo, Minato-ku, Tokyo, Japan; Division of Clinical Research and Development, Therapeutic Product Development, Amgen Limited, Minato-ku, Tokyo, Japan Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science ,The University of Tokyo, Minato-ku, Tokyo, Japan; Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science ,The University of Tokyo, Minato-ku, Tokyo, Japan; Department of Advanced Molecular and Cell Therapy, Medical Institute of Bioregulation, Kyushu University, Higashi-ku, Fukuoka, Japan Faculty of Pharmaceutical Science, Teikyo University, Tsukui-gun, Kanagawa, Japan Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science ,The University of Tokyo, Minato-ku, Tokyo, Japan Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan Department of Industrial Science and Technology, Science University of Tokyo, Chiba, Tokyo, Japan Division of Cell Processing, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Nakakoma-gun, Yamanashi, Japan * Corresponding author; email: taniken{at}bioreg.kyushu-u.ac.jp. Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have poor prognosis despite intensive therapeutic intervention. Recently, imatinib, a BCR-ABL tyrosine kinase inhibitor, has been proven to be an effective treatment for Ph+ ALL, but nearly all patients rapidly acquire resistance. High-dose imatinib administration might overcome this resistance, however, systemic toxicities would likely limit this approach. Therefore, a new delivery system allowing for the specific targeting of imatinib is urgently needed. Since almost all Ph+ ALL cells express CD19 on their surface, we have developed an immunoliposome carrying anti-CD19 antibody (CD19-liposomes). The internalization efficiency of the CD19-liposomes approached 100% in all Ph+ ALL cells but was very low in CD19-negative cells. The cytocidal effect of imatinib-encapsulated CD19-liposomes (imatinib-CD19-liposomes) on Ph+ ALL cell lines and primary leukemia cells from Ph+ ALL patients was much greater than that of imatinib with or without control liposomes. Importantly, the imatinib-CD19-liposomes did not affect the colony formation of CD34-positive hematopoietic cells, even at inhibitory concentration of free imatinib. Taken together, this data clearly demonstrates that the imatinib-CD19-liposomes induced specific and efficient death of Ph+ ALL cells. This new therapeutic approach might be a useful treatment for Ph+ ALL with fewer side effects than free imatinib. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Targeting ALL leukemia Jerald P. Radich Blood 2004 104: 1235-1236. [Full Text] [PDF] This article has been cited by other articles: A. Kotani, D. Ha, J. Hsieh, P. K. Rao, D. Schotte, M. L. den Boer, S. A. Armstrong, and H. F. Lodish miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221 Blood, November 5, 2009; 114(19): 4169 - 4178. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020